December 11, 2022
Poster
2022 ASH Poster - A Phase 1/2 Open-label, Multicenter, Dose Escalation and Expansion Study of the Myeloid Kinase Inhibitor HM43239 (Tuspetinib) in Patients with Relapsed or Refractory Acute Myeloid Leukemia: View Poster